We take our tagline seriously. We’re disrupting the traditional CRO model with our collaborative, personalised approach to drug discovery. With customers in over 27 countries globally, our aim is to become the most trusted research partner to biotherapeutic innovators. Backed by brilliant minds, we offer a range of in vitro bioassay services from immunology, bioanalytical, cell line engineering, development of bioassays, to safety and efficacy assessments. Working across inflammation, auto-immunity, immuno-oncology and oncology, we focus on novel and emerging therapeutic classes. We embrace change and drive innovation with unique services, like our customisable IndEx-2 cell line platform, to stay ahead of the curve. Our assays recreate disease stare pathologies as faithfully as possible, driving your drug discovery journey forward.
Rommelag USA
BLOW-FILL-SEAL ADVANCED ASEPTIC LIQUID PACKAGING Rommelag® provides Advanced Aseptic liquid packaging solutions with its Blow/Fill/Seal technology. BFS is the standard packaging technology for preservative-free unit-dose ophthalmic drugs. It has the highest Aseptic Assurance Level available. BFS is now available with Preservative Free Multi-Dose (PFMD) formats. mail.romus@rommelag.com or visit us at www.rommelag.com
Ritedose Corp
Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com | The Ritedose Corporation is an industry leader in the CDMO, generic and 503B outsourcing markets. Founded in 1995 in Columbia, S.C., we use aseptic cGMP manufacturing and advanced blow-fill-seal (BFS) technology to ensure sterile, efficient and safe unit dose delivery. With its recent land acquisition, Ritedose operates entirely from a 130-acre campus in South Carolina. Ritedose has more than 575 employees and occupies 273,000 square feet of development, manufacturing and packaging space, driving an annual capacity of 2+ billion units. With the newly announced formation of Ritedose Performance Park and the buildout of an additional 225,000 sq ft Central Distribution Center, Ritedose will occupy over a half million sq ft under roof. Our highly touted, 27-year track record since 2012, includes delivery of more than 10 billion doses without a single interruption, and an exceptional inspection history and compliance record as noted by regulators, including the FDA. The Ritedose CDMO team shepherds products from early phase clinicals to commercial scale in an average 18 to 20 days from formulation to shipment and deploys rigorous environmental controls eliminating problems before they occur. The division produces both branded and generic solutions. Ritedose produces suspensions and emulsions for the inhalation, ophthalmic, otic and oral markets. Ritedose Pharmaceuticals provides an uninterrupted, reliable supply chain of unit dose generic inhalation medication for wholesalers and major pharmacy chains across the U.S. Our competitive pricing, aseptic manufacturing platform and packaging innovations allow our partners to feel confident in the products they offer to service patients. Our 503B outsourcing division delivers on-demand, pre-filled critical care syringe products that save valuable time in the pharmacy for clinicians who are stretched thin. Our innovative packaging allows for extended product dating of up to 360 days at room temperature storage. Appropriate product labeling and reliable concentrations facilitate safe patient care reducing potential bedside errors.
Revolution Medicines
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
RepPrep.ai
RepPrep.ai is a purpose-built AI platform for medical sales teams, transforming physician, claims, and research data into actionable insights and pre-call plans within seconds. With seamless integration, customized datasets, and continuously updated information, RepPrep.ai equips organizations to optimize targeting, enhance ROI, and streamline sales effectiveness.
Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.
Raycision Medical Technology Co.,Ltd.
Raycision Medical Technology was founded by a team of scientists and engineers with entrepreneurial spirit. Nurtured within a research laboratory environment, our endeavors flourish through a steadfast commitment to innovation, collaboration, and the pursuit of excellence in craftsmanship. Raycision offers cutting-edge multimodality imaging technology and image-guided radiation platform for preclinical studies. Our patented RAYCISION image-guided radiation therapy (IGRT) system, tailored specifically for small animal radiotherapy, streamlines the entire process from tumor detection, treatment planning, dose calculation, treatment delivery and ultimately, to response assessment.
Quest Healthcare, A Division of Quest Products LLC
Quest Healthcare is a specialty healthcare company focused on improving patient comfort, protecting skin integrity, and supporting quality of life through clinically relevant, patient-centered solutions. We partner with WOC nurses, clinicians, and caregivers across acute care, long-term care, rehabilitation, home health, and hospice settings to address the real-world challenges of wound management, skin breakdown, and incontinence-associated complications. Our approach blends thoughtful product design with education and collaboration, helping care teams deliver consistent, compassionate care while supporting clinical best practices. A cornerstone of our portfolio is Alocane® Plus, a topical wound and skin care product designed to provide fast-acting comfort while supporting the healing environment. Alocane Plus combines OTC maximum-strength lidocaine with aloe vera and moisturizing agents to help relieve pain, burning, and irritation commonly associated with wounds, compromised skin, and periwound tissue. Its non-greasy, easy-to-apply formulation integrates smoothly into existing wound care protocols without interfering with dressings. WOC clinicians utilize Alocane Plus to enhance patient comfort, support adherence to care plans, and address pain-related barriers that can negatively impact healing and overall outcomes. Quest Healthcare also offers Doctor Butler’s®, a trusted brand dedicated to gentle, effective skin care solutions for patients experiencing incontinence. Doctor Butler’s Soothing Incontinence Spray is a touchless application used to calm irritated, inflamed skin resulting from repeated exposure to moisture, urine, and stool. The convenient formulation acts as a skin protectant to temporarily relieve chafed or cracked skin while providing additional moisture barrier properties. This formulation makes it especially beneficial for fragile or compromised skin. By helping to soothe discomfort and support the skin barrier, the spray plays a crucial role in prevention and management strategies for incontinence-associated dermatitis. Complementing the spray is Doctor Butler’s Cleansing Lotion, a rinse-free moisturizing cleanser designed for routine perineal care and sensitive skin. The lotion effectively removes contaminants while helping maintain the skin’s natural moisture balance, reducing reliance on harsh soaps and excessive wiping. Its gentle formulation supports skin integrity and dignity while promoting consistent, standardized hygiene practices across care settings. Used together, Doctor Butler’s products help clinicians establish reliable skin care routines that reduce breakdown risk and improve patient comfort. What sets Quest Healthcare apart is our commitment to clinical education and partnership. We recognize that effective wound and continence care extends beyond products alone. By working alongside WOC professionals, we aim to support evidence-informed practice, improve patient experiences, and reduce preventable skin complications. At WOCN, Quest Healthcare is proud to share solutions that prioritize comfort, integrity, and compassionate care—because protecting the skin means protecting the patient.
Quantum-Si
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com | Quantum-Si is redefining proteomic analysis by making single molecule protein analysis fast, simple, and accessible to every lab, everywhere. Powered by our core technology, Next-Gen Protein Sequencing™, Quantum-Si’s single-molecule platform enables kinetic measurements, revealing not just which proteins are present, but how they behave and interact within biological systems. By removing the complexity of traditional workflows like gels, Western blots, or specialized core facilities, Quantum-Si brings powerful, quantitative proteomic capabilities directly to the benchtop. It’s a new approach to protein analysis, one that provides both identification and quantitative understanding in a single platform with unparalleled resolution. With Quantum-Si, researchers gain deeper clarity into the molecular mechanisms that shape life, and the human condition. This advancement supports a new era of functional proteomics, accelerating discoveries across research, therapeutic development, and beyond.
Quanterix Corp
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.